Zobrazeno 1 - 10 of 117 pro vyhledávání: '"Todd D. Armstrong"'
1
Akademický článek
Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways
Autor: Won Jin Ho, Rossin Erbe, Ludmila Danilova, Zaw Phyo, Emma Bigelow, Genevieve Stein-O’Brien, Dwayne L. Thomas, Soren Charmsaz, Nicole Gross, Skylar Woolman, Kayla Cruz, Rebecca M. Munday, Neeha Zaidi, Todd D. Armstrong, Marcelo B. Sztein, Mark Yarchoan, Elizabeth D. Thompson, Elizabeth M. Jaffee, Elana J. Fertig
Publikováno v: Genome Biology, Vol 22, Iss 1, Pp 1-23 (2021)
Abstract Background The majority of pancreatic ductal adenocarcinomas (PDAC) are diagnosed at the metastatic stage, and standard therapies have limited activity with a dismal 5-year survival rate of only 8%. The liver and lung are the most common sit
Externí odkaz: https://doaj.org/article/4cd9bd7ed8eb40259c3e0e809f852646
Zobrazit plný text záznamu
2
Akademický článek
Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies
Autor: Victoria M. Kim, Alex B. Blair, Peter Lauer, Kelly Foley, Xu Che, Kevin Soares, Tao Xia, Stephen T. Muth, Jennifer Kleponis, Todd D. Armstrong, Christopher L. Wolfgang, Elizabeth M. Jaffee, Dirk Brockstedt, Lei Zheng
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Immune checkpoint inhibitors are not effective for pancreatic ductal adenocarcinoma (PDAC) as single agents. Vaccine therapy may sensitize PDACs to checkpoint inhibitor treatments. Annexin A2 (ANXA2) is a pro-metastasis protein, p
Externí odkaz: https://doaj.org/article/54280b372b12429ab75fc9c756155e36
Zobrazit plný text záznamu
3
Akademický článek
Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection
Autor: Daniel Delitto, Daniel J. Zabransky, Fangluo Chen, Elizabeth D. Thompson, Jacquelyn W. Zimmerman, Todd D. Armstrong, James M. Leatherman, Reecha Suri, Tamara Y. Lopez-Vidal, Amanda L. Huff, Melissa R. Lyman, Samantha R. Guinn, Marina Baretti, Luciane T. Kagohara, Won Jin Ho, Nilofer S. Azad, William R. Burns, Jin He, Christopher L. Wolfgang, Richard A. Burkhart, Lei Zheng, Mark Yarchoan, Neeha Zaidi, Elizabeth M. Jaffee
Publikováno v: OncoImmunology, Vol 10, Iss 1 (2021)
Tumor involvement of major vascular structures limits surgical options in pancreatic adenocarcinoma (PDAC), which in turn limits opportunities for cure. Despite advances in locoregional approaches, there is currently no role for incomplete resection.
Externí odkaz: https://doaj.org/article/97094383247048c2ade5ce77d37edcab
Zobrazit plný text záznamu
4
Akademický článek
Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development
Autor: Neeha Zaidi, Mariya Soban, Fangluo Chen, Heather Kinkead, Jocelyn Mathew, Mark Yarchoan, Todd D. Armstrong, Shozeb Haider, Elizabeth M. Jaffee
Publikováno v: JCI Insight, Vol 5, Iss 17 (2020)
In prior studies, we delineated the landscape of neoantigens arising from nonsynonymous point mutations in a murine pancreatic cancer model, Panc02. We developed a peptide vaccine by targeting neoantigens predicted using a pipeline that incorporates
Externí odkaz: https://doaj.org/article/ecdd87c059d54eb1a318c0283e12f92b
Zobrazit plný text záznamu
5
Akademický článek
Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen
Autor: Zoila A. Lopez-Bujanda, Matthew G. Chaimowitz, Todd D. Armstrong, Jeremy B. Foote, Leisha A. Emens, Charles G. Drake
Publikováno v: OncoImmunology, Vol 9, Iss 1 (2020)
Immunotherapy has shown limited success in prostate cancer; this may be partially explained by its immunosuppressive tumor microenvironment (TME). Although androgen-deprivation therapy (ADT), the most common treatment for prostate cancer, initially p
Externí odkaz: https://doaj.org/article/62899deb7ed141a49f8b381e321fce93
Zobrazit plný text záznamu
6
Akademický článek
MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity.
Autor: Mark Yarchoan, Aditya A Mohan, Lauren Dennison, Teena Vithayathil, Amanda Ruggieri, Gregory B Lesinski, Todd D Armstrong, Nilofer S Azad, Elizabeth M Jaffee
Publikováno v: PLoS ONE, Vol 14, Iss 10, p e0224600 (2019)
Mitogen-activated protein kinase (MAPK) kinase (MEK) is an integral component of the RAS pathway and a therapeutic target in RAS-driven cancers. Although tumor responses to MEK inhibition are rarely durable, MEK inhibitors have shown substantial acti
Externí odkaz: https://doaj.org/article/deeb6c87dad04ce283915d1ea8fb3199
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje